Table 2.
Variables | Overall survival
|
HR (95%) CI |
---|---|---|
Univariate analysis
| ||
P-value | ||
Gender | ||
Male vs female | 0.35 | 1.316 (0.740–2.341) |
Age | ||
≤60 vs >60 | 0.955 | 0.986 (0.609–1.598) |
Pathological types | ||
SCC vs ADC | 0.824 | 0.943 (0.562–1.583) |
Primary tumor (T) stage | ||
T1–2 vs T3–4 | 0.020* | 0.549 (0.331–0.911) |
Lymph node (N) metastasis | ||
N0–1 vs N2–3 | 0.172 | 0.699 (0.418–1.168) |
Clinical tumor/node/metastasis stage | ||
II vs III | 0.354 | 0.772 (0.446–1.335) |
RKIP expression | ||
Low vs high | 0.003* | 1.810 (0.617–5.313) |
| ||
Variables |
Overall survival
|
HR (95%) CI |
Multivariate analysis
| ||
P-value
| ||
| ||
Primary tumor (T) stage | ||
T1–2 vs T3–4 | 0.386 | 0.767 (0.421–1.398) |
RKIP expression | ||
Low vs high | 0.042# | 1.830 (1.023–3.276) |
Note:
P<0.05 by univariate Cox proportional hazards regression model,
P<0.05 by multivariate Cox proportional hazards regression model.
Abbreviations: ADC, adenocarcinoma; HR, hazard ratio; RKIP, Raf kinase inhibitor protein; SCC, squamous cell carcinoma.